Prima BioMed (NASDAQ:IMMP) Share Price Crosses Below 50-Day Moving Average – Here’s What Happened

Prima BioMed Ltd (NASDAQ:IMMP) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $0.44 and traded as low as $0.4205. Prima BioMed shares last traded at $0.4446, with a volume of 2,034,964 shares changing hands.

Prima BioMed News Roundup

Here are the key news stories impacting Prima BioMed this week:

• Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Bernstein Liebhard, Faruqi & Faruqi, Bronstein Gewirtz & Grossman, Levi & Korsinsky, and SueWallSt, publicized securities class action claims against Immutep, keeping legal overhang front and center for investors. Article Title
• Negative Sentiment: The lawsuit appears tied to allegations around Immutep’s TACTI-004 lung-cancer program, with one notice citing the trial being stopped for futility after enrolling only about half its target, which may reinforce concerns about clinical execution and future prospects. Article Title
• Neutral Sentiment: One market note reported essentially no short interest in the name, so there is no meaningful short-selling signal to offset the legal-driven narrative.

Analyst Ratings Changes

Several analysts have issued reports on IMMP shares. Citizens Jmp lowered Prima BioMed from an “outperform” rating to a “market perform” rating in a research note on Friday, March 13th. Maxim Group lowered shares of Prima BioMed from a “buy” rating to a “hold” rating in a report on Friday, March 13th. Robert W. Baird cut shares of Prima BioMed from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $7.00 to $1.00 in a research note on Friday, March 13th. Finally, Wall Street Zen raised shares of Prima BioMed to a “hold” rating in a report on Saturday, April 18th. Three analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Prima BioMed presently has an average rating of “Reduce” and a consensus price target of $5.50.

Prima BioMed Price Performance

The stock has a 50 day simple moving average of $0.44 and a 200 day simple moving average of $1.79.

Prima BioMed (NASDAQ:IMMP) last issued its earnings results on Friday, January 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter. The firm had revenue of $1.37 million for the quarter.

Hedge Funds Weigh In On Prima BioMed

A hedge fund recently raised its stake in Prima BioMed stock. Jane Street Group LLC raised its holdings in shares of Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 51,574 shares of the biotechnology company’s stock after purchasing an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent SEC filing. 2.32% of the stock is currently owned by hedge funds and other institutional investors.

About Prima BioMed

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.